{"acute kidney injury": 2.67, "adrenal insufficiency": 14.43, "adrenocorticotropic hormone deficiency": 31.16, "adverse event": 4.0, "anaemia": 2.1, "arthritis": 2.39, "atrioventricular block complete": 3.87, "autoimmune colitis": 57.47, "autoimmune haemolytic anaemia": 13.21, "autoimmune hepatitis": 16.79, "autoimmune hypothyroidism": 90.89, "autoimmune nephritis": 86.18, "autoimmune thyroiditis": 13.45, "blood thyroid stimulating hormone increased": 7.02, "central nervous system lesion": 4.12, "cholangitis sclerosing": 21.23, "cholecystitis": 2.16, "colitis": 15.5, "cortisol decreased": 15.58, "cytokine release syndrome": 2.66, "dermatitis": 3.23, "dermatitis bullous": 2.94, "diabetes mellitus": 2.39, "diabetic ketoacidosis": 7.15, "drug effective for unapproved indication": 14.0, "drug resistance": 2.24, "drug-induced liver injury": 3.68, "encephalitis": 5.94, "encephalitis autoimmune": 27.56, "eosinophilic fasciitis": 82.22, "eyelid ptosis": 5.13, "febrile neutropenia": 2.55, "fulmit type 1 diabetes mellitus": 37.71, "gastritis": 2.53, "gastrointestinal toxicity": 6.98, "general physical health deterioration": 3.21, "guillain-barre syndrome": 2.93, "haematotoxicity": 3.33, "haemophagocytic lymphohistiocytosis": 5.69, "hepatic cytolysis": 2.32, "hepatitis": 8.57, "hepatitis cholestatic": 2.21, "hepatotoxicity": 8.96, "hydronephrosis": 4.13, "hyperthyroidism": 8.23, "hypertransaminasaemia": 8.88, "hypophysitis": 43.61, "hypopituitarism": 13.51, "hypothyroidism": 20.83, "immune thrombocytopenia": 3.61, "immune-mediated adrenal insufficiency": 14.0, "immune-mediated adverse reaction": 233.79, "immune-mediated arthritis": 208.33, "immune-mediated dermatitis": 112.82, "immune-mediated encephalitis": 96.54, "immune-mediated enterocolitis": 91.18, "immune-mediated gastritis": 156.9, "immune-mediated hepatic disorder": 19.88, "immune-mediated hepatitis": 162.74, "immune-mediated hyperthyroidism": 86.83, "immune-mediated hypophysitis": 75.08, "immune-mediated hypothyroidism": 110.82, "immune-mediated lung disease": 226.52, "immune-mediated myasthenia gravis": 154.87, "immune-mediated myocarditis": 208.47, "immune-mediated myositis": 167.62, "immune-mediated nephritis": 111.04, "immune-mediated neuropathy": 69.84, "immune-mediated pancreatitis": 107.47, "immune-mediated thyroiditis": 292.32, "immune-mediated uveitis": 93.83, "inappropriate schedule of product administration": 4.54, "interstitial lung disease": 3.5, "lichen planus": 7.66, "lichenoid keratosis": 16.99, "lymphocytic hypophysitis": 50.28, "maligt neoplasm progression": 22.26, "mucosal inflammation": 4.38, "multi-organ disorder": 30.61, "myasthenia gravis": 26.17, "myasthenia gravis crisis": 26.15, "myasthenic syndrome": 34.88, "myocarditis": 5.29, "myopathy": 3.12, "myositis": 17.22, "nephritis": 31.85, "nephropathy toxic": 4.09, "neutropenia": 2.38, "nodule": 2.22, "ocular myasthenia": 47.22, "off label use": 2.51, "ophthalmoplegia": 9.97, "organising pneumonia": 14.59, "palmar-plantar erythrodysaesthesia syndrome": 3.71, "pancytopenia": 2.5, "pemphigoid": 18.85, "performance status decreased": 2.46, "pericardial effusion": 2.12, "pleural effusion": 2.2, "pneumonitis": 30.49, "pneumothorax": 2.01, "polyarthritis": 17.6, "polymyalgia rheumatica": 13.75, "posterior reversible encephalopathy syndrome": 3.5, "prescribed underdose": 4.91, "primary hypothyroidism": 109.5, "product use in unapproved indication": 6.49, "product use issue": 6.68, "proteinuria": 5.25, "psoriasis": 2.84, "pulmonary fibrosis": 2.59, "pulmonary mass": 2.28, "pulmonary toxicity": 7.41, "radiotherapy": 24.68, "renal cyst": 3.18, "renal tubular necrosis": 6.11, "respiratory failure": 2.33, "sarcoidosis": 11.16, "secondary adrenocortical insufficiency": 21.92, "sjogren's syndrome": 10.68, "skin toxicity": 28.77, "stevens-johnson syndrome": 3.33, "stomatitis": 2.34, "therapy non-responder": 8.95, "therapy partial responder": 111.23, "thyroiditis": 20.59, "toxic epidermal necrolysis": 7.23, "troponin increased": 2.55, "tubulointerstitial nephritis": 14.84, "tumour hyperprogression": 323.29, "tumour pseudoprogression": 183.97, "type 1 diabetes mellitus": 34.93, "uveitis": 3.92, "vasculitis": 2.82, "vitiligo": 49.57}